About
Creating exceptional medicines with structure and ReSOLVE®
Since its inception in 2020, Ventus rapidly advanced two lead programs from target screening to successful completion of Phase 1 trials in less than five years, commenced a phase 2 program for VENT-02 in Parkinson’s disease, and is imminently starting several additional Phase 2 trials in osteoarthritis in obese patients for VENT-02, and lupus and treatment-refractory rheumatoid arthritis for VENT-03.
“As we discover more molecules and more pathways, Ventus’ skills in getting the structure of these molecules, finding the pockets, identifying lead compounds, it’s amazing the possibilities of what could be.”
– Judith Lieberman, MD, PhD, Co-Founder
Our highly experienced leadership team has deep expertise in drug discovery and clinical development and has collectively been involved in the discovery, development, and commercialization of several approved drugs. Ventus has an exceptional track record of execution, and our multiple Phase 2 trials will generate impactful data over the next 12-18 months.
